Aurora says other suitors are now reading its books, and Curaleaf's $5 offer still isn't enough

Aurora Cannabis' board unanimously told shareholders on October 14 to keep rejecting Curaleaf's revised hostile offer, and this time it added something new. Aurora said its financial advisor has approached several potential counterparties and signed confidentiality and standstill agreements with multiple groups that are now reviewing company information. It did not name anyone or say whether a formal competing bid exists, and it cautioned that the review may not produce a deal.

Curaleaf's offer, raised by 25 percent earlier in the month, is worth about $5 per Aurora share on paper: $1 in cash plus 0.4013 Curaleaf shares, with a possible maximum of $6. Curaleaf calls that an 86 percent premium to Aurora's price before the bid went public and pitches a combined company in 17 countries with more than $1.5 billion in annual revenue and at least $40 million in yearly cost savings. The offer stays open until December 4.

Aurora's counter is that the structure pays shareholders largely in Curaleaf stock while giving Curaleaf access to Aurora's own cash, and that the claimed synergies are unproven. The board says it will issue another recommendation once it has weighed the alternatives, and it urged shareholders not to tender in the meantime.

Why it matters: a stock-heavy bid is only as good as the buyer's shares, and in a sector where valuations swing with every rescheduling headline, that is a real risk to hold. Aurora telling the market there is a process underway also raises the chance that Curaleaf has to pay up in cash or walk. Treat the December 4 date as the next real checkpoint.